ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
|
|
- Shanon Murphy
- 5 years ago
- Views:
Transcription
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1
2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Spain) Eurican SHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Austria and Germany) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of lyophilisate contains: Active substances: Minimum Maximum Canine Distemper virus, strain BA CCID 50 * CCID 50 * Canine Adenovirus type 2, strain DK CCID 50 * CCID 50 * Canine Parvovirus type 2, strain CAG CCID 50 * CCID 50 * Canine Parainfluenza virus type 2, strain CCID 50 * CCID 50 * CGF 2004/75 (* CCID 50 : 50% cell culture infective dose) One dose (1ml) of suspension contains: Active substances: Inactivated Leptospira interrogans serogroup and serovar Canicola strain Activity acc. to Ph. Eur.447* Inactivated Leptospira interrogans serogroup and serovar Icterohaemorrhagiae strain Activity acc. to Ph. Eur.447* Inactivated Leptospira interrogans serogroup and serovar Grippotyphosa strain Grippo Mal Activity acc. to Ph. Eur.447* * 80% protection in hamsters Excipients: For the full list of excipients, see section PHARMACEUTICAL FORM Lyophilisate and suspension for suspension for injection. Beige to pale yellow lyophilisate and opalescent, homogenous suspension 4. CLINICAL PARTICULARS 4.1 Target species Dogs 2
3 4.2 Indications for use, specifying the target species Active immunisation of dogs to: - prevent mortality and clinical signs caused by Distemper virus - prevent mortality and clinical signs caused by infectious canine hepatitis virus, - reduce viral excretion during respiratory disease caused by canine adenovirus type 2, - prevent mortality, clinical signs and viral excretion caused by canine parvovirus, - reduce viral excretion caused by canine parainfluenza virus type 2, - prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae - prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. - prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. Onset of immunity: 2 weeks for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains. Protection has been demonstrated against canine parvovirus type 2a, 2b and 2c for at least one year either by challenge (type 2b) or serology (type 2a and 2c). * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. 4.3 Contraindications None 4.4 Special warnings for each target species None. 4.5 Special precautions for use Special precautions for use in animals Vaccinate only healthy animals. Apply usual aseptic procedures. After vaccination, the live CAV-2 and CPV vaccine strains can transiently be shed without adverse consequence for in-contact animals. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 4.6 Adverse reactions (frequency and seriousness) Immediately after injection, a slight swelling ( 2 cm) at the injection site may commonly be observed, usually regressing within 1-6 days. This can, on some occasions, be accompanied by slight pruritus, heat and pain at the injection site. Transient lethargy and emesis may also be observed. Uncommon reactions such as anorexia, polydipsia, hyperthermia, diarrhoea, muscle tremor, muscle weakness and injection site cutaneous lesions may be observed. 3
4 As with any vaccine, rare hypersensitivity reactions may occur. In such cases, appropriate symptomatic treatment should be provided. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 4.7 Use during pregnancy, lactation or lay Can be used during pregnancy 4.8 Interaction with other medicinal products and other forms of interaction Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Merial's rabies vaccine in dogs from 12 weeks of age. In that case, the efficacy against Leptospira Icterohaemorrhagiae was demonstrated only for the reduction of renal lesions and bacterial excretion, and the efficacy against Leptospira Grippotyphosa was demonstrated only for the reduction of renal carriage, renal lesions and bacterial excretion. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. 4.9 Amounts to be administered and administration route Aseptically reconstitute the contents of the lyophilisate with the suspension for injection. Shake well before use. The entire contents of the reconstituted vial should be administered as a single dose. The reconstituted content shall be an opalescent yellow to orange suspension. Inject a 1-ml dose subcutaneously according to the following schedule: Primary vaccination: Two injections separated by an interval of 4 weeks from 7 weeks of age. In cases where high levels of maternally derived antibodies are suspected by the veterinarian and the primary vaccination course was completed before 16 weeks of age, a third injection using a Merial vaccine containing Distemper, Adenovirus and Parvovirus is recommended from 16 weeks of age, at least 3 weeks after the second injection. Revaccination: Administer one dose 12 months after completion of the primary vaccination course. Dogs should be revaccinated with a single booster dose on an annual basis Overdose (symptoms, emergency procedures, antidotes), if necessary No adverse reactions other than those mentioned in section 4.6 were observed after administration of a 10-fold overdose of the lyophilisate and 2-fold overdose of the suspension. 4
5 4.11 Withdrawal period(s) Not applicable. 5. IMMUNOLOGICAL PROPERTIES Pharmacotherapeutic group: Live viral and inactivated bacterial vaccines ATC vet code: QI07AI02 Vaccine against distemper, adenoviroses (CAV-1 and CAV-2), parvovirosis and parainfluenza type 2 respiratory infections (attenuated) and Leptospira (inactivated) in dogs. After administration, the vaccine induces an immune response against distemper, adenoviroses (CAV-1 and CAV-2), parvovirosis, parainfluenza type 2 respiratory infections and Leptospira interrogans serogroup Canicola, Leptospira interrogans serogroup Icterohaemorrhagiae and Leptospira kirschneri serogroup Grippotyphosa leptospirosis in the dog demonstrated by challenge and by the presence of antibodies. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Lyophilisate Casein hydrolysate Gelatin Dextran 40 Dipotassium phosphate Potassium dihydrogen phosphate Potassium hydroxide Sorbitol Sucrose Water for injection Suspension Potassium chloride Sodium chloride Potassium dihydrogen phosphate Disodium phosphate dihydrate Water for injections 6.2 Incompatibilities Do not mix with any other veterinary medicinal product except the suspension supplied for use with the product. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years Shelf life after reconstitution according to directions: use immediately 6.4. Special precautions for storage Store and transport refrigerated (2 C-8 C) Do not freeze. Protect from light. 5
6 6.5 Nature and composition of immediate packaging Type I glass vials with chlorobutyl stoppers, sealed with aluminium caps. Plastic box of 10 vials (glass) of lyophilisate (1 dose) and 10 vials (glass) of suspension (1 ml). Plastic box of 25 vials (glass) of lyophilisate (1 dose) and 25 vials (glass) of suspension (1 ml). Plastic box of 50 vials (glass) of lyophilisate (1 dose) and 50 vials (glass) of suspension (1 ml). Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER MERIAL 29 Avenue Tony Garnier Lyon France 8. MARKETING AUTHORISATION NUMBER(S) 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10 DATE OF REVISION OF THE TEXT PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable 6
7 ANNEX III LABELLING AND PACKAGE LEAFLET 7
8 A. LABELLING 8
9 PARTICULARS TO APPEAR ON THE OUTER PACKAGE Box of 10 doses: 10 vials (glass) of 1 dose of lyophilisate and 10 vials (glass) of 1 ml of solvent for suspension. Box of 25 doses: 25 vials (glass) of 1 dose of lyophilisate and 25 vials (glass) of 1 ml of solvent for suspension. Box of 50 doses: 50 vials (glass) of 1 dose of lyophilisate and 50 vials (glass) of 1 ml of solvent for suspension. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Spain) Eurican SHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Austria and Germany) 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Attenuated distemper virus CCID 50 Attenuated canine adenovirus type CCID 50 Attenuated canine parvovirus CCID 50 Attenuated canine parainfluenza type 2 virus CCID 50 Inactivated Leptospira strains*... activity acc. Ph.Eur.447** *Leptospira serogroup and serovar Canicola, Icterohaemorrhagiae, Grippotyphosa ** 80% of protection in hamsters 3. PHARMACEUTICAL FORM Lyophilisate and suspension for suspension for injection. 4. PACKAGE SIZE 10 doses : 10x1 dose lyophilisate + 10x1ml suspension. 25 doses : 25x1 dose lyophilisate + 25x1ml suspension. 50 doses : 50x1 dose lyophilisate + 50x1ml suspension. 5. TARGET SPECIES Dogs 6. INDICATION(S) 7. METHOD AND ROUTE(S) OF ADMINISTRATION 9
10 Subcutaneous use Read the package leaflet before use. 8. WITHDRAWAL PERIOD Not applicable 9. SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use. 10. EXPIRY DATE EXP {month/year} Use immediately after reconstitution. 11. SPECIAL STORAGE CONDITIONS Store and transport refrigerated (2 C-8 C) Do not freeze Protect from light 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY Disposal: Read the package leaflet before use. 13. THE WORDS FOR ANIMAL TREATMENT ONLY AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE For animal treatment only - To be supplied only on veterinary prescription. 14. THE WORDS KEEP OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER MERIAL 29 Avenue Tony Garnier Lyon France 16. MARKETING AUTHORISATION NUMBER(S) 10
11 17. MANUFACTURER S BATCH NUMBER Lot 11
12 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Lyophilisate:1 dose 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi (for Spain) Eurican SHPPi 2 -L multi (for Austria and Germany) 2. QUANTITY OF THE ACTIVE SUBSTANCE(S) DHPPi 2 (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) CHPPi 2 (for Belgium, Estonia, France, Luxemburg and Portugal) MHPPi 2 (for Spain) SHPPi 2 (for Austria and Germany) Read package leaflet before use. 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 1 dose 4. ROUTE(S) OF ADMINISTRATION SC 5. WITHDRAWAL PERIOD Not applicable 6. BATCH NUMBER Lot 7. EXPIRY DATE EXP {month/year} 8. THE WORDS FOR ANIMAL TREATMENT ONLY 12
13 For animal treatment only 13
14 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Suspension:1 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi (for Spain) Eurican SHPPi 2 -L multi (for Austria and Germany) 2. QUANTITY OF THE ACTIVE SUBSTANCE(S) L multi Read package leaflet before use. 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 1 ml 4. ROUTE(S) OF ADMINISTRATION SC 5. WITHDRAWAL PERIOD Not applicable 6. BATCH NUMBER Lot: 7. EXPIRY DATE EXP {month/year} 8. THE WORDS FOR ANIMAL TREATMENT ONLY For animal treatment only 14
15 B. PACKAGE LEAFLET 15
16 PACKAGE LEAFLET FOR: Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Spain) Eurican SHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Austria and Germany) 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder : MERIAL 29 Avenue Tony Garnier Lyon France Manufacturer responsible for batch release: MERIAL, Laboratoire Porte des Alpes Rue de l'aviation Saint-Priest France 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia and Sweden) Eurican CHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Belgium, Estonia, France, Luxemburg and Portugal) Eurican MHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Spain) Eurican SHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Austria and Germany) 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) One dose of lyophilisate contains: Minimum Maximum Canine Distemper virus, strain BA CCID 50 * CCID 50 * Canine Adenovirus type 2, strain DK CCID 50 * CCID 50 * Canine Parvovirus type 2, strain CAG CCID 50 * CCID 50 * Canine Parainfluenza virus type 2, strain CCID 50 * CCID 50 * CGF 2004/75 (* CCID 50 : 50% cell culture infective dose) One dose (1ml) of suspension contains: Inactivated Leptospira interrogans serogroup and serovar Canicola strain Activity acc. to Ph. Eur.447* Inactivated Leptospira interrogans serogroup and serovar Icterohaemorrhagiae strain Activity acc. to Ph. Eur.447* 16
17 Inactivated Leptospira interrogans serogroup and serovar Grippotyphosa strain Grippo Mal Activity acc. to Ph. Eur.447* * 80% protection in hamsters Beige to pale yellow lyophilisate and opalescent, homogenous suspension 4. INDICATIONS Active immunisation of dogs to: - prevent mortality and clinical signs caused by Distemper virus - prevent mortality and clinical signs caused by infectious canine hepatitis virus, - reduce viral excretion during respiratory disease caused by canine adenovirus type 2, - prevent mortality, clinical signs and viral excretion caused by canine parvovirus, - reduce viral excretion caused by canine parainfluenza virus type 2, - prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae - prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. - prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. Onset of immunity: 2 weeks for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains. Protection has been demonstrated against canine parvovirus type 2a, 2b and 2c for at least one year either by challenge (type 2b) or serology (type 2a and 2c). * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. 5. CONTRAINDICATIONS None 6. ADVERSE REACTIONS Immediately after injection, a slight swelling ( 2 cm) at the injection site may commonly be observed, usually regressing within 1-6 days. This can, on some occasions, be accompanied by slight pruritus, heat and pain at the injection site. Transient lethargy and emesis may also be observed. Uncommon reactions such as anorexia, polydipsia, hyperthermia, diarrhoea, muscle tremor, muscle weakness and injection site cutaneous lesions may be observed. As with any vaccine, rare, occasional hypersensitivity reactions may occur. In such cases, appropriate symptomatic treatment should be provided. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 17
18 If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon. 7. TARGET SPECIES Dogs 8. DOSAGE FOR EACH SPECIES, ROUTEAND METHOD OF ADMINISTRATION After reconstitution, inject a 1-ml dose subcutaneously according to the following schedule: Primary vaccination: Two injections separated by an interval of 4 weeks from 7 weeks of age. In cases where high levels of maternally derived antibodies are suspected by the veterinarian and the primary vaccination course was completed before 16 weeks of age, a third injection using a Merial vaccine containing Distemper, Adenovirus and Parvovirus is recommended from 16 weeks of age, at least 3 weeks after the second injection. Revaccination: Administer one dose 12 months after completion of the primary vaccination course. Dogs should be revaccinated with a single booster dose on an annual basis. 9. ADVICE ON CORRECT ADMINISTRATION Aseptically reconstitute the contents of the lyophilisate with the suspension for injection. Shake well before use. The entire contents of the reconstituted vial should be administered as a single dose. The reconstituted content shall be an opalescent yellow to orange suspension. 10. WITHDRAWAL PERIOD Not applicable 11. SPECIAL STORAGE PRECAUTIONS Keep out of the sight and reach of children. Store and transport refrigerated (2 C-8 C). Do not freeze Protect from light. Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. Shelf-life after reconstitution according to directions: use immediately. 12. SPECIAL WARNINGS Special precautions for use in animals: Vaccinate only healthy animals. Apply usual aseptic procedures. After vaccination, the live CAV-2 and CPV vaccine strains can transiently be shed without adverse consequence for in-contact animals. Special precautions to be taken by the person administering the veterinary medicinal product to animals: 18
19 In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Pregnancy: Can be used during pregnancy Interaction with other medicinal products and other forms of interaction: Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Merial s rabies vaccine in dogs from 12 weeks of age. In that case, the efficacy against Leptospira Icterohaemorrhagiae was demonstrated only for the reduction of renal lesions and bacterial excretion, and the efficacy against Leptospira Gripotyphosa was demonstrated only for the reduction of renal carriage, renal lesions and bacterial excretion. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis Overdose: No adverse reactions other than those mentioned in section adverse reactions were observed after administration of a 10-fold overdose of the lyophilisate and 2-fold overdose of the suspension. Incompatibilities: Do not mix with any other veterinary medicinal product except the suspension supplied for use with the product. 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED 15. OTHER INFORMATION Plastic box of 10 vials (glass) of lyophilisate (1 dose) and 10 vials (glass) of suspension(1 ml). Plastic box of 25 vials (glass) of lyophilisate (1 dose) and 25 vials (glass) of suspension (1 ml). Plastic box of 50 vials (glass) of lyophilisate (1 dose) and 50 vials (glass) of suspension (1 ml). Not all pack sizes may be marketed. 19
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DAPPi lyophilisate and solvent for suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax Rabies suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac L4, suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax RCP lyophilisate and solvent for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac L4 suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Purevax RCP FeLV lyophilisate and solvent for suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Proteq West Nile suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1
More informationMUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS 8, rue Claude Bourgelat Parc d'activités de la Grande Marche CS 70611 35306 Fougères FRANCE MUTUAL RECOGNITION PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Ducat (DE: Nobivac RC, SE : Nobivac Ducat vet.) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Per
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ProteqFlu suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rispoval 3 BRSV Pi3 BVD Lyophilisate and suspension for suspension for injection for cattle 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Circovac emulsion and suspension for emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationMUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS 8, rue Claude Bourgelat Parc d'activités de la Grande Marche CS 70611 35306 Fougères FRANCE MUTUAL RECOGNITION PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ProteqFlu-Te Suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose contains:
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT VANGUARD CPV-L 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Quantity per 1 ml dose Active substance(s): Live attenuated canine Parvovirus, strain NL-35-D, low passage,
More informationLeptospirosis has changed. Here's how to meet the new threat
Leptospirosis has changed. Here's how to meet the new threat Introducing Nobivac L 4 The UK s first tetravalent leptospirosis vaccine Serovars identified by positive MAT test results* from clinical submissions
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Piro lyophilisate and solvent for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationPART 1 B SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
BIOVETA, a. s. Komenského 212, 683 23 Ivanovice na Hané, Czech Republic, e-mail: obchod@bioveta.cz PART 1 B SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET SUMMARY OF PRODUCT CHARACTERISTICS
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus L4 suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BTVPUR suspension for injection for sheep and cattle. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versifel FeLV, suspension for injection for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Bovela lyophilisate and solvent for suspension for injection for cattle. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Myxo-RHD lyophilisate and solvent for suspension for injection for rabbits 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RESPIPORC FLUpan H1N1 suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AFTOVAXPUR DOE emulsion for injection for cattle, sheep and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis Prequenza suspension for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Canigen L4 suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BIOCOM P Vet, suspension for injection for minks (all MS except DK) BIOVAC-BP, suspension for injection for minks (DK) 2.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ingelvac CircoFLEX suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (1 ml)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Respiporc FLU3 suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4 lyophilisate and solvent for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Coliprotec F4/F18 lyophilisate for oral suspension for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV M Hyo emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 ml contains: Active
More informationBovine Herpes Virus type 1 (BoHV-1), strain Difivac (ge-negative), to induce a geometric mean seroneutralizing titre of at least 1:160 in cattle
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rispoval IBR-Marker Inactivated 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (2ml) contains Active Substance: Bovine Herpes Virus type 1 (BoHV-1), strain
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Versifel FeLV, suspension for injection for cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains: Active substance: Inactivated feline leukaemia
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Suvaxyn PCV suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 2 ml contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BioEquin H, emulsion for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vaccine dose (1 ml) contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis OR inac emulsion for injection for chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 0.25
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rispoval IBR-Marker Vivum, Lyophilisate and diluent for suspension for injection for cattle Rispoval IBR-Marker Live (for
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis Influenza H5N2 emulsion for injection for chickens. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Suvaxyn M.hyo - Parasuis, suspension for injection for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: per 2 ml dose Inactivated Mycoplasma
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis IB Primo QX lyophilisate and solvent for suspension for chickens Nobilis IB Primo QX lyophilisate for suspension
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equip WNV emulsion for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/17
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/17 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis Pesti emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis StrepE, lyophilisate and solvent for suspension for injection, for horses 2. QUALITATIVE AND QUANTITATIVE
More informationBeurteilungsbericht zur Veröffentlichung. (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) Versican L3R. Zulassungsdatum:
Beurteilungsbericht zur Veröffentlichung (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) Versican L3R Zulassungsdatum: 21.02.2012 Zulassungsnummer: PEI.V.11603.01.1 Datum der Erstellung des öffentlichen Beurteilungsberichts:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RHINISENG suspension for injection for pigs. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ERYSENG PARVO suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml contains:
More informationPaul-Ehrlich-Institut DE/V/0022/001/II/023/G Page 1
Paul-Ehrlich-Institut DE/V/0022/001/II/023/G Page 1 PACKAGE LEAFLET Rispoval IBR-Marker Vivum Lyophilisate and diluent for suspension for injection for cattle. 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ZULVAC 8 Ovis suspension for injection for sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose of 2 ml of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8, 10/2012] Cevac MD HVT_2016-October-18 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cevac MD HVT suspension and solvent for suspension for injection
More informationPackage leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate
Package leaflet: Information for the patient Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate Read all of this leaflet carefully before you are given this medicine because
More informationENCEFAL-VAC SUMMARY OF PRODUCT CHARACTERISTICS
ENCEFAL-VAC SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ENCEFAL-VAC Live lyophilised vaccine for chickens 2. QUALITATIVE AND QUANTITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AviProSALMONELLA VAC E Lyophilisate for suspension for chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin
PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need
More information[Version 8, 10/2012] ANNEX I SUMMARY OF PROPOSED PRODUCT CHARACTERISTICS
[Version 8, 10/2012] ANNEX I SUMMARY OF PROPOSED PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Uniferon 200 mg/ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSummary of Product Characteristics
Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Novamune concentrate and solvent for suspension for injection for chickens 2 QUALITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HIPRABOVIS IBR MARKER LIVE lyophilisate and solvent for suspension for injection for cattle. 2. QUALITATIVE AND
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CaniLeish lyophilisate and solvent for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ERAVAC emulsion for injection for rabbits 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 0.5 ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Part I.B page 1 of 7 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/7 Part I.B page 2 of 7 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis PCV emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MS-H Vaccine eye drops suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: One dose (30 µl)
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Outer carton Multi-pack 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve
More informationMUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS 8, rue Claude Bourgelat Parc d'activités de la Grande Marche CS 70611 35306 Fougères FRANCE MUTUAL RECOGNITION PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET BioEquin H, emulsion for injection for horses 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR
More informationPaul-Ehrlich-Institut
Paul-Ehrlich-Institut DE/V/0021/001/II/014 Page 1 Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines FINALISATION REPORT ON VARIATION TYPE II PRODUCT DETAILS Name of products Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT INCURIN 1 mg tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis IB 4-91 lyophilisate for suspension for chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of
More information[Version 8.1, 01/2017] ANNEX I. SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8.1, 01/2017] ANNEX I. SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis SE live lyophilisate for use in drinking water for chickens 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Credelio 56 mg chewable tablets for dogs (1.3 2.5 kg) Credelio 112 mg chewable tablets for dogs (>2.5 5.5 kg) Credelio
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Semintra 4 mg/ml oral solution for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active substance:
More information1. What Panzyga is and what it is used for
Package leaflet: Information for the user Panzyga, 100 mg/ml solution for infusion Human Normal Immunoglobulin (IVIg) This medicine is subject to additional monitoring. This will allow quick identification
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Octaplex 500 IU powder and solvent for solution for infusion Human prothrombin complex Octaplex 1000 IU powder and solvent for solution for infusion Human prothrombin
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis ND Clone 30 live 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: per dose * Live Newcastle disease virus, strain Clone 30 ³ 6.0 log 10 ELD
More informationPorcilis Ery+Parvo+Lepto
Beurteilungsbericht zur Veröffentlichung (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) Porcilis Ery+Parvo+Lepto Zulassungsdatum: 01.09.2016 Zulassungsnummer: PEI.V.11798.01.1 Datum der Erstellung des öffentlichen
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve 50 mg/ml solution for injection for dogs (AT, BE, BG, CY, CZ, DE, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO,
More information1. NAME OF THE VETERINARY MEDICINAL PRODUCT. ALPHA JECT micro 6 emulsion for injection for Atlantic salmon 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE VETERINARY MEDICINAL PRODUCT ALPHA JECT micro 6 emulsion for injection for Atlantic salmon 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance(s): 1 dose (0.05 ml) contains: Formaldehyde
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. STAMARIL, powder and solvent for suspension for injection in pre-filled syringe Yellow fever vaccine (Live)
PACKAGE LEAFLET: INFORMATION FOR THE USER STAMARIL, powder and solvent for suspension for injection in pre-filled syringe Yellow fever vaccine (Live) Read all of this leaflet carefully before you or your
More informationTiorfan Hidrasec Tiorfix Tiorfast 100 mg PACKAGE LEAFLET
Tiorfix Tiorfast 100 mg PACKAGE LEAFLET 1 Tiorfix Tiorfast 100 mg Package leaflet: Information for the user 100 mg hard capsules Racecadotril Read all of this leaflet carefully before you start taking
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Fevaxyn Pentofel, suspension for injection for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 1 ml
More informationPART 1.B SPC, LABELLING AND PACKAGE LEAFLET
TRAMADOG, solution for injection Decentralised Procedure D195 February 2018 V3 Tramadol HCl 50 mg/ml Part 1.B SPC, Labelling and Package Leaflet PART 1.B SPC, LABELLING AND PACKAGE LEAFLET 1B- 1 ANNEX
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurifel RCPFeLV Powder and solvent for emulsion for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CZ, Vigophos 100 mg / ml + 0.05 mg / ml solution for injection for cattle (AT, BE, DE, DK, ES, HU, IE, IT, NL, PL,
More informationSmokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Procycline LA 200 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance Oxytetracycline (as dihydrate) 200.0
More informationPackage leaflet: Information for the user. Zoviduo 50 mg/g and 10 mg/g cream. Aciclovir and Hydrocortisone
The PL includes alternative texts for different legal status in different countries as follows: -Boxed texts are only applicable for OTC versions. -[Grey-shaded texts in brackets] are only applicable for
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Aqupharm 1 (9 mg/ml) solution for injection/infusion (UK/IE) Natriumklorid Animalcare 9 mg/ml solution for injection/infusion
More informationB. PACKAGE LEAFLET. Page 1 of 6
B. PACKAGE LEAFLET Page 1 of 6 PACKAGE LEAFLET Prilocard 1.25 mg, 2.5 mg, 5 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE
More informationBuserelin animedica mg/ml Injektionslösung für Rinder, Pferde, Kaninchen
1. NAME OF THE VETERINARY MEDICINAL PRODUCT Buserelin animedica 0,004 mg/ml Injektionslösung für Rinder, Pferde, Kaninchen (Germany) Buserelin animedica 0.004 mg/ml Injektionslösung für Rinder, Pferde,
More informationOverview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Human proteins g/l g/l of which human immunoglobulin at least to. 180 IU/ml 180 IU/vial
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT UMAN BIG 180 IU/ml Solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. UMAN BIG 180 IU/1
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DUPHALYTE Solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Composition per ml VITAMINS
More information2. What do you need to know before you use Octanate
Package leaflet: Information for the user Octanate 50 IU/ml Powder and Solvent for Solution for Injection Human Coagulation Factor VIII Octanate 100 IU/ml Powder and Solvent for Solution for Injection
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BE, CY, CZ, DE, EL, FR, HU, LU, NL, PT, SK, UK: KELACTIN 50 microgram/ml oral solution for dogs and cats DK, FI, IS, NO, SE:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF VETERINARY MEDICINAL PRODUCT HESKA PERIOceutic Gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each unit dose contains: 2.1 Active substance Doxycycline
More information